(2S)-3-(4-aminophenyl)-2-(phenylmethoxycarbonylamino)propanoic acid | 228261-84-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-3-(4-aminophenyl)-2-(phenylmethoxycarbonylamino)propanoic acid
• CAS: 228261-84-5
• 化学式: C₁₇H₁₈N₂O₄
• 分子量: 314.341
• InChiKey: PDOXYRMYJYXZQV-HNNXBMFYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  102
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  二碳酸二叔丁酯 、 (2S)-3-(4-aminophenyl)-2-(phenylmethoxycarbonylamino)propanoic acid 在 三乙胺 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 12.0h， 以17%的产率得到(2S)-3-[4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]-2-(phenylmethoxycarbonylamino)propanoic acid
  参考文献：
  名称：

  Design and evaluation of Trypanosoma brucei metacaspase inhibitors

  摘要：

  Metacaspase (MCA) is an important enzyme in Trypanosoma brucei, absent from humans and differing significantly from the orthologous human caspases. Therefore MCA constitutes a new attractive drug target for antiparasitic chemotherapeutics, which needs further characterization to support the discovery of innovative drug candidates. A first series of inhibitors has been prepared on the basis of known substrate specificity and the predicted catalytic mechanism of the enzyme. In this Letter we present the first inhibitors of TbMCA2 with low micromolar enzymatic and antiparasitic activity in vitro combined with low cytotoxicity. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.099
• 作为产物：
  描述：

  (2S)-3-(4-硝基苯基)-2-(苯基甲氧基羰基氨基)丙酸 在 tin(ll) chloride 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以98%的产率得到(2S)-3-(4-aminophenyl)-2-(phenylmethoxycarbonylamino)propanoic acid
  参考文献：
  名称：

  Design and evaluation of Trypanosoma brucei metacaspase inhibitors

  摘要：

  Metacaspase (MCA) is an important enzyme in Trypanosoma brucei, absent from humans and differing significantly from the orthologous human caspases. Therefore MCA constitutes a new attractive drug target for antiparasitic chemotherapeutics, which needs further characterization to support the discovery of innovative drug candidates. A first series of inhibitors has been prepared on the basis of known substrate specificity and the predicted catalytic mechanism of the enzyme. In this Letter we present the first inhibitors of TbMCA2 with low micromolar enzymatic and antiparasitic activity in vitro combined with low cytotoxicity. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.099

文献信息

• NOVEL FUSED-RING CARBOXYLIC ACID COMPOUND OR SALT THEREOF, AND MEDICINAL USE THEREOF
  申请人：THE GREEN CROSS CORPORATION

  公开号：EP0712844A1

  公开（公告）日：1996-05-22

  A novel carboxylic acid compound having a condensed ring, which is represented by the formula (I) wherein each symbol is as defined in the specification, a pharmacologically acceptable salt thereof, a pharmaceutical composition thereof and pharmaceutical use thereof. The novel carboxylic acid compound having a condensed ring and pharmacologically acceptable salt thereof of the present invention have superior GPIIb/IIIa antagonism in mammals inclusive of human; can be administered orally; have long life in blood and low toxicity; and show less side-effects. Accordingly, they are extremely useful for the prophylaxis and treatment of thrombotic diseases and other diseases.

  一种具有缩合环的新型羧酸化合物，由式 (I) 表示 其中各符号如说明书中所定义；其药理上可接受的盐；其药物组合物；其药物用途。本发明的具有缩合环的新型羧酸化合物及其药理学上可接受的盐在哺乳动物（包括人类）中具有优异的 GPIIb/IIIa 拮抗作用；可口服给药；在血液中的存活期长且毒性低；副作用小。因此，它们对于预防和治疗血栓性疾病和其他疾病极为有用。
• THIADIAZOLE AMIDE MMP INHIBITORS
  申请人：PHARMACIA & UPJOHN COMPANY

  公开号：EP1021424B1

  公开（公告）日：2003-02-26
• US5635527A
  申请人：——

  公开号：US5635527A

  公开（公告）日：1997-06-03
• US5753670A
  申请人：——

  公开号：US5753670A

  公开（公告）日：1998-05-19
• US5830869A
  申请人：——

  公开号：US5830869A

  公开（公告）日：1998-11-03